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Tbjective: Extracorporeal life support is used in 3% to 8% of infants and children
fter cardiac surgery. B-type natriuretic peptide may have utility as a biomarker in
hese patients. The objective of this study was to investigate potential associations
etween changes in B-type natriuretic peptide during trials off extracorporeal life
upport and clinical outcome.
ethods: Ten infants and children requiring extracorporeal life support after cardiac
urgery were studied prospectively. Before separation from extracorporeal life
upport, a shunt was placed in the circuit, allowing for temporary trials off life
upport. Serum lactate, arterial–venous oxyhemoglobin saturation difference, and
-type natriuretic peptide levels were determined before each trial off life support
nd at the end of each trial off life support, and the ability to predict postoperative
utcome from these data was evaluated.
esults: During trials off extracorporeal life support, lactate, the arterial–venous
xyhemoglobin saturation difference, and B-type natriuretic peptide levels in-
reased above pre-trial values (P  .05). Only the arterial–venous oxyhemoglobin
aturation difference predicted successful separation from extracorporeal life sup-
ort after a trial (P  .05). There were no associations between long-term outcome
nd alterations in lactate and the arterial–venous oxyhemoglobin saturation differ-
nce during the final trials off life support. However, an increase in B-type
atruiretic peptide levels during the final trial off life support (trial/pre-trial ratio of
1) had a sensitivity of 80% and a specificity of 100% for predicting the need for
n unplanned operation or death within 3 months (P  .05).
onclusion: B-type natriuretic peptide determinations may be a useful tool for
linicians caring for infants and children requiring extracorporeal life support after
ardiac surgery.
xtracorporeal life support (ECLS) is used in 3% to 8% of infants and children
after corrective or palliative surgery for congenital cardiac defects.1-5 Al-
though historically a rescue therapy, technologic advances and accumulated
linical experience have expanded the indications for ECLS to permit earlier
nitiation and even prophylactic treatment of low cardiac output syndrome.6-9
onsequently, patients supported with ECLS are an increasingly heterogeneous
roup, with some who require only time for recovery and others who require further
nterventions. Distinguishing between these types of patients is important to mini-
ize the duration of ECLS and to ensure that patients requiring further investiga-
ions and interventions are identified. Thus, much of the clinical focus during ECLS
s aimed at assessing recovery of cardiovascular function. One common method
nvolves trials off ECLS that are achieved by placing a shunt in the ECLS circuit,
llowing mechanical support to be temporarily stopped, but keeping the cannulas
he Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 5 1179
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Dnd circuit components free of thrombosis and ready for
mmediate resumption. During these trials off ECLS, car-
iovascular function is assessed by observing the hemody-
amic response and through the measurement of various
arkers of cardiac output, such as lactate, central venous
emoglobin saturation, acid–base status, and urine output.3
nfortunately, none of these factors has been shown to
dequately predict either a readiness to separate from ECLS
r the need for further intervention.1 Thus, novel biomark-
rs that might aid in these assessments are needed.
B-type natriuretic peptide (BNP) is a 32-amino acid
olypeptide hormone with diuretic, natriuretic, and vasoac-
ive properties. As a cardiac hormone produced by the atria
nd ventricles in response to myocyte stretch, it has been
hown to have unique clinical utility as a biomarker and is
hus widely used in the management of adult cardiac dis-
ase, with an emerging use in pediatric cardiac disease.10-15
n fact, BNP has been studied in adult and pediatric patients
equiring mechanical cardiac support.16-20 However, the
alue of BNP levels in predicting successful separation
rom ECLS or in predicting outcome after surgery, includ-
ng the need for further interventions, has not been
stablished.
Thus, the objectives of this study were (1) to determine
hether alterations in BNP during trials off ECLS were
ssociated with our ability to separate patients from ECLS
nd (2) to investigate potential associations between
hanges in BNP during trials off ECLS and outcome. We
rospectively studied 9 infants and children who required
CLS after cardiac surgery. Systemic arterial plasma BNP
eterminations were made before and during each trial off
CLS, and whether a change in BNP could predict separa-
ion from ECLS, and/or postoperative outcome was
valuated.
aterials and Methods
his prospective cohort study was conducted in the Pediatric
ardiac Intensive Care Unit (PCICU) at the University of Califor-
ia, San Francisco, between March 2005 and June 2006. Patients
ith congenital cardiac defects undergoing surgical repair were
nrolled and patients requiring postoperative ECLS were included
n the study.
The patients were followed up during their entire course in the
Abbreviations and Acronyms
AVdO2  arterial–venous oxyhemoglobin saturation
difference
BNP  B-type natriuretic peptide
CPB  cardiopulmonary bypass
ECLS  extracorporeal life support
PCICU pediatric cardiac intensive care unitCICU. The perioperative anesthesia management, cardiopulmo- m
180 The Journal of Thoracic and Cardiovascular Surgery ● Novary bypass (CPB) strategy, and subsequent PCICU management
ollowed standard institutional practices. An on-service team that
as blinded to the BNP values made all decisions regarding
atient management.
Written informed consent was obtained from the patients’
arents or guardians before enrollment of the patients into the
tudy. The Institutional Review Board at the University of Cali-
ornia, San Francisco, reviewed and approved this study.
ndications for ECLS
he indications for ECLS included (1) the inability to separate a
atient from CPB, necessitating the initiation of ECLS in the operat-
ng room, (2) the elective initiation of ECLS in the operating room for
ow cardiac output after discontinuing CPB, (3) the development of
efractory low cardiac output syndrome in PCICU, or (4) postopera-
ive cardiac arrest, with ECLS used as a part of cardiopulmonary
esuscitation. Signs of low cardiac output in the operating room or
ntensive care unit that resulted in the initiation of ECLS included
ustained systemic hypotension and/or persistent metabolic acidosis
efractory to medical management.
CLS
ur techniques for circulatory support have been described in
etail previously.21 The ECLS circuit was a Medtronic Bio-
edicus Portable Cardiopulmonary Bypass System 1000, consisting
f a centrifugal pump Bio-Console model 550 (BP-50 Bio-Pump;
edtronic Inc, Anaheim, Calif) and a hollow-fiber membrane
xygenator (Mini-max Plus or Affinity NT, Medtronic), in which
he whole surface was heparin-bonded. Arterial (left atrial or
ortic) and venous (right or common atrial) cannulas were placed
hrough either a transcervical or transsternal approach. Left ven-
ricular decompression with an additional left atrial cannula was used
electively for patients with biventricular hearts and severe left ven-
ricular dysfunction. Systemic–pulmonary shunts were kept open dur-
ng ECLS. For patients with adequate pulmonary function and oxy-
enation requiring only left ventricular support without an
xygenator, a single venous cannula was placed in the left atrium and
he arterial cannula was placed in the ascending aorta. Circuit flow
as targeted at 80 to 120 mL · kg1 · min1 or 150 mL · kg1 ·
in1 for shunt-dependent patients. Inotropes were discontinued or
ecreased during ECLS support. Heparin infusions were used in most
ases to maintain an activated clotting time of 180 to 220 seconds.
eparation from ECLS
he decision to discontinue ECLS was based on patients recover-
ng adequate cardiovascular function. To assess native cardiovas-
ular function, we placed a shunt or bridge between the arterial and
enous cannulas. With the use of 3-way connectors, ECLS flow
as diverted away from the patient, but full flow was maintained
cross the remainder of the circuit, allowing for trials off ECLS
ithout removal of the cannulas. The cannulas were flushed during
his time with a continuous infusion of heparin solution. During
rials off ECLS, an observer blinded to the BNP data collected
emodynamic and biochemical data. In most trials, echocardiog-
aphy was performed to assess ventricular function. ECLS was
iscontinued, with removal of the cannulas, if the cardiac team
elieved that cardiovascular function was adequate. These assess-
ents were variably based on the hemodynamic, echocardio-
ember 2007
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Draphic, and biochemical data obtained during the trials off ECLS,
nd the decisions were individualized for each patient. In general,
period of stable hemodynamics with the support of fluid volume
oading and inotropic agents, the appearance of improvement in
ardiac function by echocardiography as compared with the period
efore ECLS initiation, and minimal changes in venous oxygen
aturation and acid–base status were sought. All members of the
ardiac team making these decisions were blinded to the BNP data.
utcomes
good short-term outcome was defined as separation from ECLS
fter a trial off ECLS. Poor short-term outcome was defined as the
eed for resumption of ECLS after a trial off ECLS. Good long-
erm outcome was defined as the absence of death or unplanned
peration within 3 months of separation from ECLS. Poor long-
erm outcome was defined as an unplanned operation within 3
onths or death within 3 months of separation from ECLS. BNP
evels, hemodynamic data, and other biochemical values were
valuated for their association with these end points.
ata Collection
lood samples were obtained from an arterial catheter preopera-
ively, before each trial off ECLS, and at the end of each trial off
CLS. The samples were immediately placed on ice in chilled
thylenediamine tetraacetic acid tubes and centrifuged at 3000 rpm
or 15 minutes at 4°C. Separated plasma was stored at 20°C.
ithin 7 days of obtaining the sample, the plasma was thawed to
oom temperature, and BNP levels were measured with a com-
ercially available fluorescence immunoassay (Triage Meter Plus;
iosite Diagnostics, San Diego, Calif). The measurable range of
NP on this device is between 5 and 5000 pg/mL. The estimated
oefficient of variation for the assay is 9.2% to 11.4%.
Clinical and biochemical data were prospectively collected at
ach sampling point and once daily thereafter by an observer
linded to the BNP data. The clinical data collected included
emographics, CPB time, myocardial ischemic time during the
peration, duration of ECLS, duration of each weaning trial, du-
ation of mechanical ventilation, inotrope dose, mean systemic
rterial pressure, central venous pressure, urine output, and fluid
alance. Biochemical data included arterial and venous blood
ases, base deficit, and serum lactate levels. The duration of
echanical ventilation was quantified as the number of ventilator-
ree days within the first 28 days after the operation, so as to avoid
onfounding the data with patients who died while receiving
echanical ventilation.
alculations
notrope use was quantified by a score adapted from Wernovsky
nd associates.22 The score was calculated from the level of
notropic support the patients were receiving (in micrograms per
ilogram per minute) at each sampling point according to the
ollowing equation: dopamine  dobutamine  ([epinephrine 
orepinephrine]  100)  (milrinone  20). The arterial–venous
xyhemoglobin saturation difference (AVdO2) was calculated as
he co-oximetric arterial oxyhemoglobin saturation minus the cen-
ral venous oxyhemoglobin saturation. E
The Journal of Thoracicnalysis of the Data
ata are described as mean  standard deviation, range, or per-
entage, as appropriate. Differences in the continuous variables
etween good outcome and poor outcome subgroups were tested
ith the Student t test or Mann–Whitney U test. Differences of
ariables between subgroups within category were tested with the
isher exact test. Contingency tables were formulated to determine
he sensitivity value, specificity value, positive predictive value,
nd negative predictive value of changes in serum BNP, lactate,
nd the AVdO2. Differences of variables within groups at two
ifferent time points were compared by paired t test. Correlations
etween variables were performed by the Spearman rank correla-
ion method. Statistical analyses were performed with the use of
rism (GraphPad Software, Inc, San Diego, Calif).
esults
atients
total of 11 patients required ECLS after cardiac surgery
nd were enrolled in the study. Two patients died without
ndergoing a trial off ECLS and thus were excluded from
he analysis. One patient underwent 2 separate operations, 3
onths apart, and required ECLS after each operation. For
he analysis, this patient is considered separately on each
dmission (Patients 6 and 7, Table 1). The patients’ demo-
raphic data, cardiac defects, surgical repairs, indications
or ECLS, types of ECLS, ECLS durations, and long-term
utcomes are outlined in Table 1. The mean intraoperative
ypass time was 123 minutes 43 (range 69–188 minutes),
ith a mean crossclamp time of 61 minutes  30 (range
6–116 minutes). Four (40%) patients had single ventricle
hysiology. In 3 (30%) patients, ECLS consisted of
echanical ventricular support without an oxygenator; the
emaining 7 patients received mechanical ventricular sup-
ort with an oxygenator. There was no association between
he use of an oxygenator and outcome.
rials of Patients off ECLS
or the 10 patients studied, there were 18 trials off ECLS.
NP levels were obtained during 16 of these trials. Five
50%) patients underwent only 1 trial off ECLS. The mean
uration of the trials was 94 minutes  102 (range 9–340
inutes). Hemodynamic and biochemical data before (pre-
rial) and during trials off ECLS (trial) are shown in Table 2.
hen all trials were taken together, heart rate and central
enous pressure increased, and mean arterial pressure de-
reased from pre-trial values (P  .05). In addition, the
notrope score increased during trials off ECLS (P  .05).
urthermore, serum lactate, the AVdO2, and serum BNP
alues increased above pre-trial values (P .05). There was
o correlation between the duration of the trials off ECLS
nd any of the biochemical values or hemodynamic indices.
eparation of Patients From ECLS
ine (90%) patients were ultimately able to separate from
CLS. One patient who underwent trials off ECLS died
and Cardiovascular Surgery ● Volume 134, Number 5 1181
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Dithout separating from ECLS. In both the poor and good
hort-term outcome groups, mean arterial pressure de-
reased, and central venous pressure, heart rate, and inotro-
ic score increased during the trials (P  .05).
Biochemical changes during the trials for each group are
hown in Figure 1. Serum BNP and lactate levels tended to
ncrease in the poor short-term outcome group, but these
hanges did not reach significance (Figure 1). However, the
VdO2 was significantly higher in the poor short-term out-
ome group than in the good short-term outcome group
Figure 1; P  .05). In fact, an AVdO2 of greater than 40
uring a trial off ECLS had a sensitivity of 100% and a
pecificity of 70% for predicting a poor short-term outcome
P  .05).
ong-term Outcomes
he long-term outcome for each patient can be seen in
able 1. There were 5 (50%) poor long-term outcomes and
(50%) good long-term outcomes. One patient (patient 1,
able 1) required an unplanned operation within 3 months
fter ECLS and died within 6 months of ECLS. The un-
lanned operation is considered the single poor outcome for
his patient. Thus, 3 (30%) patients died within 3 months
fter ECLS, and 2 (20%) patients required an unplanned
peration within 3 months after ECLS.
Patients with poor long-term outcomes had a longer
ABLE 1. Patient demographics
atient No. Age Sex Weight (kg)
1 5 mo M 9 DORV, uncom
2 4 d F 3 HLHS
3 3 y M 14.5 Unbalanced A
syndrome,
4 1 d M 2.6 TGA
5 5 d M 2.34 VSD, ASD, hy
isthmus/tra
6* 3 mo F 3.2 VSD, ASD, AS
ascending
obstruction
7* 5 mo F 4 AS, AI, aortic
8 3 mo F 3.72 DORV, hypop
Taussig–Bi
9 2 mo F 4.8 ALCAPA
10 2 d M 3.2 TAPVR, restri
CLS, Extracorporeal life support; DORV, double-outlet right ventricle; VS
LHS, hypoplastic left heart syndrome; AVC, atrioventricular canal; AV, atri
SD, atrial septal defect; AS, aortic valve stenosis; AI, aortic insufficiency;
rom the pulmonary artery; TAPVR, total anomalous pulmonary venous reortic crossclamp time (43 minutes  14 vs 78 minutes  t
182 The Journal of Thoracic and Cardiovascular Surgery ● Nov9; P  .05) and more trials off ECLS (1.4  0.5 vs 2.8 
.1; P  .05) than patients with good long-term outcomes.
here were no significant differences between the two
roups in age, weight, type of cardiac defect, preoperative
NP levels, bypass time, ECLS duration, or hospital days.
n addition, there were no significant differences between
he groups in pre-trial or trial mean arterial pressures, cen-
ral venous pressures, heart rates, urine output, or inotrope
cores.
Days in the PCICU tended to be longer in the poor
utcome group, but the difference did not reach significance
25 days  13.6 vs 13.4 days  6.6; P  .12). Patients in
he poor outcome group had fewer mechanical ventilation–
ree days than patients in the good outcome group (8.4 days 
.1 vs 20 days  5.7; P  .05).
Biochemical changes during the final trial off ECLS
or patients with good and poor long-term outcomes are
hown in Figure 2. There were no differences in the
VdO2 or in the change in lactate during the trials be-
ween groups (Figure 2). Pre-trial lactate levels were
reater in the poor long-term outcome group than in the
ood long-term outcome group (1.8 mmol/L  1.0 vs 1.0
mol/L  0.21; P  .11), but the values were within the
ormal range and were not predictive of outcome. Abso-
ute lactate levels during the trials were also not predic-
n Repair
d VSD, RVOT Intracardiac repair, takedown of repair
Modified Norwood operation stage I
heterotaxy
nia
Fontan operation, AV valve repair,
focalization of hepatic veins
Arterial switch
astic aortic
rse arch
VSD closure, aortic arch reconstruction
poplasia of
, aortic arch
VSD closure, aortic arch reconstruction
obstruction Ross–Konno, ascending aorta augumentation
RV,
omaly
Modified Norwood operation
Translocation of left coronary to aorta
ASD Complete repair
ntricular septal defect; RVOT, right ventricular outflow tract obstruction;
ricular; TGA, transposition of great arteries; CPB, cardiopulmonary bypass;
ht ventricle; OR, operating room; ALCAPA, anomalous left coronary artery
The same patient with two different admissions 3 months apart.Lesio
mitte
VC,
asple
popl
nsve
, hy
aorta
arch
lastic
ng an
ctive
D, ve
ovent
RV, rigive of outcome.
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DThe change in BNP during a trial, as defined by the ratio
f the trial to pre-trial BNP level, was significantly higher in
he poor long-term outcome group than in the good long-
erm outcome group (Figure 2; P  .05). BNP levels de-
reased from pre-trial levels during the final trials off ECLS
n all 5 patients with a good long-term outcome (from 388
g/mL  309 to 306 pg/mL  246; P  .05) and increased
uring the final trials in 4 of the 5 patients with a poor
ong-term outcome (from 638 pg/mL  310 to 953 pg/mL 
75; P  .07). The 1 patient (patient 2, Table 1) with a poor
ong-term outcome who had a decrease in BNP during the
nal trial off ECLS was separated from ECLS but 48 hours
ater had support withdrawn owing to multisystem organ
ailure. In fact, an increase in BNP during the final trial off
ABLE 1. Continued.
Indication for ECLS Use of oxygenator
ostoperative cardiac arrest Yes
ow cardiac output syndrome Yes
ow cardiac output syndrome Yes
nability to separate from CPB No
ow cardiac output syndrome Yes
ostoperative cardiac arrest No
nability to separate from CPB Yes
ow cardiac output after CPB
(elective initiation in OR)
No
nability to separate from CPB No
nability to separate from CPB Yes
ABLE 2. Hemodynamic and biochemical data in all pa-
ients before (pre-trial) and during (trial) trials0020off ECLS
Pre-trial Trial P value
actate (mmol/L) 1.44 0.71 2.6  1.9 .005
notropic score 15.6 5.2 21.1  9.1 .002
R (beats/min) 136 17 152  21 .008
AP (mm Hg) 62 11 50  10 .002
VP (mm Hg) 10 4 15 4 .0001
cvO2 (%) 72  14 50  22 .0005
VdO2 (%) 28.5 14.2 44.2  20.2 .004
NP (pg/mL) 581 382 777  637 .03
R, Heart rate; MAP, mean arterial pressure; CVP, central venous pres-
ure; ScvO , central venous oxygen saturation; AVdO , arterial–venoust
2 2
xyhemoglobin saturation difference; BNP, B-type natriuretic peptide.
The Journal of ThoracicCLS (trial/pre-trial ratio of 1) had a sensitivity of 80%
nd a specificity of 100% for predicting a poor long-term
utcome (P  .05).
iscussion
hese data indicate that BNP may have clinical utility as a
iomarker for infants and children requiring ECLS after
ardiac surgery. Although BNP levels during trials off
CLS did not predict subsequent separation from ECLS, an
ncrease in BNP during the final trial off ECLS was asso-
iated with the need for an unplanned operation or death
ithin 3 months. Interestingly, no other changes during
rials off ECLS were associated with these long-term out-
omes, and thus BNP may reflect myocardial derangements
n a manner not captured by other physiologic markers.
We chose to investigate BNP because it is a cardiac
ormone integrally related to the myocardium, as opposed
o other biomarkers that reflect more global processes. BNP
s a member of a structurally related group of peptide
ormones, termed natriuretic peptides. Biosynthesis of BNP
egins with a 134-amino acid precursor, which is cleaved in
teps to form the active C-terminal 32-amino acid hormone,
NP, and the inactive N-terminal proBNP. Active BNP is
tored in the atria in specific storage organelles.23 Basal
NP levels result from continuous secretion from the atria.
ith acute myocardial distention, BNP release increases
reatly from this depletable storage pool, in a manner inde-
endent of BNP synthesis. However, under chronic condi-
ions of increased cardiac volume loading, such as conges-
LS duration (d) Long-term outcome
2 Unplanned operation within 3 mo,
death within 6 mo
7 Death with multiorgan failure 48 h after
separation from ECLS
4 No need for further intervention after
separation from ECLS
3 No need for further intervention after
separation from ECLS
10 Death, inability to wean from ECLS
4 Unplanned operation within 3 mo
8 Death within 3 mo
4 No need for further intervention after
separation from ECLS
2 No need for further intervention after
separation from ECLS
3 No need for further intervention after
separation from ECLSECive heart failure, increases in circulating BNP are
and Cardiovascular Surgery ● Volume 134, Number 5 1183
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Daintained owing to ventricular re-expression of the fetal
ene program.24-26 In addition, acute myocardial ischemia
nd inflammatory mediators, such as tumor necrosis
igure 1. Biochemical changes during trials off extracorporeal
ife support (ECLS) in patients with good and poor short-term
utcomes. A good short-term outcome was defined as the sepa-
ation from ECLS after a trial, and a poor short-term outcome was
efined as the resumption of ECLS after a trial. A, The arterial–
enous oxyhemoglobin saturation difference (AVdO2) was signif-
cantly greater in the poor short-term outcome group than the
ood short-term outcome group. B, The change in lactate during
rials is expressed as the ratio of the level during the trial
on-trial) to the level before the trial (pre-trial). The change in
actate during trials was not significantly different between
roups. C, The change in B-type natriuretic peptide (BNP) during
rials is expressed as the ratio of the level during the trial to the
evel before the trial. The change in BNP during trials was not
ignificantly different between groups.actor- and interleukin-1, result in rapid ventricular ex- C
184 The Journal of Thoracic and Cardiovascular Surgery ● Novression of BNP.26,27 The primary actions of BNP, which
re mediated by the secondary messenger cGMP, are vas-
ular smooth muscle relaxation, diuresis, and natriuresis.
igure 2. Biochemical changes during the final trials off extra-
orporeal life support (ECLS) in patients with good and poor
ong-term outcomes. Good and poor long-term outcomes were
efined as the absence and presence, respectively, of an un-
lanned cardiac operation or death with 3 months after the
peration. A, The arterial–venous oxyhemoglobin saturation dif-
erence (AVdO2) was not different between groups. B, The change
n lactate during trials is expressed as the ratio of the level
uring the trial (on-trial) to the level before the trial (pre-trial).
he change in lactate during the final trials off ECLS was not
ignificantly different between groups. C, The change in BNP
uring trials is expressed as the ratio of the level during the trial
o the level before the trial. BNP levels during the final trials off
CLS increased to a greater extent in patients with a poor
ong-term outcome than patients with a good long-term outcome.learance of BNP, which has a half-life of approximately
ember 2007
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D0 minutes, occurs through degradation by an endopepti-
ase, and by endocytosis through a specific natriuretic pep-
ide receptor, termed NPR-C. Owing to these characteris-
ics, BNP has been successfully used as a biomarker in adult
nd, to a lesser extent, pediatric cardiac disease.11-15
In fact, alterations in BNP during mechanical myocardial
upport, including support for pediatric patients after car-
iac surgery, have been investigated previously.18-20,28 In
dult patients with cardiac failure, the use of ventricular
ssist devices has been shown to decrease BNP levels and
ene expression.18,19,28 In a recent study, Huang and col-
eagues20 studied 15 pediatric patients requiring ECLS for
ardiogenic shock. Shock developed after cardiac surgery in
1 of the 15 patients. These investigators did not find an
ssociation between BNP levels during the course of ECLS
nd survival after ECLS. However, they did find that BNP
evels on the first and fourth days after separation from
CLS were significantly higher in nonsurvivors than survi-
ors.20 In contrast to the present study, these investigators
etermined BNP levels on ECLS before weaning, when the
eart was fully supported. This support may have con-
ounded any association between BNP and the underlying
ondition of the myocardium.
Cardiovascular hemodynamics may be significantly al-
ered during mechanical support of the heart, particularly
entricular loading conditions. Thus, we believed that BNP
eterminations off ECLS would have the greatest potential
linical utility. However, several factors obviate the use of
bsolute BNP values in pediatric patients after cardiac sur-
ery. Perhaps most important, the available data on BNP in
atients with congenital cardiac defects suggest that BNP
evels vary substantially depending on the specific de-
ect.29-32 Furthermore, BNP levels are altered after opera-
ions with CPB in a manner that also appears in part depen-
ent on the underlying defect, and BNP levels vary with age
ith levels highest at birth, followed by a fall in the first
weeks after birth to levels generally below that of
dults.32-34 Therefore, we chose to assess the degree of
hange in BNP during a trial to control for variability in
aseline BNP levels between patients. Although we ex-
ected BNP levels to increase in all trials off ECLS, owing
o increased cardiac volume loading, we hypothesized that
he magnitude of the change would differ significantly be-
ween patients with persistent myocardial dysfunction and
atients with adequate recovery. In fact, when all trials off
CLS were analyzed together, mean BNP levels did in-
rease (from 581 pg/mL  382 to 777 pg/mL  637; P 
05); however, quite surprisingly, in all patients with a good
ong-term outcome, BNP levels actually decreased during
rials off ECLS. The mechanism for this decrease is unclear
nd warrants further study.
Clinically, the recovery of adequate cardiovascular func-
ion is the key requirement to separate patients from ECLS. a
The Journal of Thoracicherefore, accurate clinical assessments of cardiovascular
unction during weaning from ECLS are critical. Our data
xemplify the difficulties inherent in these assessments.
uring trials off ECLS, we found significant increases in
actate, inotrope score, central venous pressure, heart rate,
NP, and the AVdO2. In addition, we found significant
ecreases in mean arterial pressure and central venous
xygen saturations. Importantly, we did not find an associ-
tion between the duration of the trials with any of the
iochemical or hemodynamic indices. However, only the
VdO2 correlated with the ability to separate from ECLS
fter a trial. We did not use a defined protocol to guide
ecisions about separating patients from ECLS, and thus it
s in fact more accurate to state that the AVdO2 was corre-
ated with the decision to separate patients from ECLS,
hereas the other factors were not. That is, patients not
eparated from ECLS after a trial may have survived sepa-
ation. Furthermore, because the cardiac team was not
linded to any of the hemodynamic or biochemical data,
ther than BNP, in reaching a decision to separate from
CLS we likely considered some or all of these factors.
evertheless, assessments of the AVdO2 are known to im-
rove the management of pediatric patients after cardiac
urgery, and thus our data suggest that this may also apply
o the subset of these patients that requires ECLS
ostoperatively.35
Despite an increase in the use of ECLS for pediatric
atients after cardiac surgery, mortality has remained at
pproximately 60% to 70%.5,9,36 In our study, 3 (30%)
atients died within 3 months of ECLS and an additional
atient died within 6 months. Previous factors that have
een reported to predict death in pediatric patients on ECLS
nclude age, gender, lactate, type of cardiac defect, inotrope
core, renal failure, hepatic failure, multisystem organ
ailure, duration of ECLS, sepsis, arrhythmia before
CLS, and the duration of mechanical ventilation before
CLS.1,3,5,36,37 None of these associations was identified in
he current study, which may relate to its small sample size.
owever, in our study only the change in BNP during the
nal trial off ECLS, predicted poor long-term outcomes.
Two patients required an unplanned operation within 3
onths of ECLS. One patient (patient 1, Table 1) required
ulmonary artery banding for excessive pulmonary blood
ow owing to left–to–right shunting, and the second patient
patient 6, Table 1) required a Ross–Konno procedure and
ortic arch augmentation for aortic stenosis, aortic obstruc-
ion, and aortic insufficiency. All patients had transesopha-
eal echocardiography performed at least once while receiv-
ng ECLS. In addition, echocardiography was performed
uring 6 of the 9 final trials off ECLS. The present study
esign does not allow comparisons between risk stratifica-
ion based on echocardiography and BNP levels. However,
fter echocardiography was performed, patients who ulti-
and Cardiovascular Surgery ● Volume 134, Number 5 1185
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Dately died or required an unplanned operation were sepa-
ated from ECLS. Although echocardiography can precisely
dentify the cardiac anatomy and function at the time of the
tudy, assessing the long-term impact of a finding (eg,
eft-to-right shunting) requires subjective judgments. Our
ata suggest that BNP may provide additional information
hat might strengthen these judgments.
The management of pediatric patients requiring ECLS
fter cardiac surgery is daunting. Unfortunately, few studies
ave put forth potential tools to aid in the management of
hese patients. This pilot study, although preliminary owing
o its sample size and heterogeneous population, suggests
hat BNP determinations during trials off ECLS allow for
isk stratification. The availability of this information before
emoval of the ECLS cannulas could allow for important
ecisions to be made at a time when full mechanical support
an be readily re-established or increased. If BNP levels
ncrease during a trial off ECLS, physicians might consider
e-evaluation of potential surgical options or consider
hether the patient would be a transplant candidate. Further
tudies are warranted to confirm and define a role for BNP
n this vulnerable patient population.
We thank Megan Tracey, PNP, Julie Bushnell, PNP, Laura
resnell, ACNP, the Pediatric Critical Care Fellows, the Cardiac
ntensive Care Nurses, the Pediatric Clinical Research Center,
dam Gorham, and Leslie Kurkjian for their invaluable assistance
ith the study.
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